SGLT-2 Inhibitors Tied to Lower Risk for Autoimmune Rheumatic Diseases in Adults With T2D
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.
According to a study, SGLT-2 inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes.
- The study involved 2,032,157 adults with type 2 diabetes from a nationwide health care database in South Korea.
- After propensity score weighting, the analysis included 1,030,088 SGLT-2 inhibitor initiators and 1,002,069 sulfonylurea initiators.
- The weighted incidence rate was 51.90 and 58.41 per 100,000 person-years in individuals initiating SGLT-2 inhibitors and sulfonylureas, respectively.
No direct quote available in the text.
Author's summary: SGLT-2 inhibitors reduce autoimmune disease risk.
More News
- When does 2026 F1 season start?
- JUST IN: Kelly Olynyk has been waived by the San Antonio Spurs
- Lightning vs. Islanders Prediction, Odds, Picks - Dec. 6
- Kelly Osbourne — Instagram Snapshot
- Kelly Vedovelli révèle sa vie amoureuse
- How to watch Islanders vs. Lightning: TV channel and streaming options for December 6
- Islanders vs. Lightning (Dec 6, 2025) Pregame
- Guadeloupean artist Kelly Sinnapah Mary wins French art prize at Art Basel Miami Beach
- Spurs' Luke Kornet out Friday
- NBA: Spurs at Timberwolves